Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.
Gerda B Toth, Csanad G Varallyay, Andrea Horvath...
https://pubmed.ncbi.nlm.nih.gov/28434822/Actively Recruiting
Led by University of Alberta · Updated on 2026-05-08
50
Participants Needed
1
Research Sites
N/A
Total Duration
Temporal lobe epilepsy TLE is a common form of epilepsy that often does not respond to medication. Surgery can potentially cure seizures for some patients, but only about 50% remain seizure-free after 10 years. This research aims to better understand which factors predict surgical success, focusing on detailed imaging of tiny regions in the hippocampus, a brain area affected in TLE. New MRI techniques using a drug called ferumoxytol are being studied to improve imaging of small blood vessels in these hippocampal areas. Participants will receive ferumoxytol Feraheme, an iron-based contrast agent approved for anemia treatment and now being tested to enhance MRI images of brain vessels. The study involves administering ferumoxytol diluted with saline via an IV pump during MRI scans. The first phase includes scanning healthy control subjects to match imaging quality from previous studies. The second phase compares the hippocampal microvasculature between control subjects and patients with TLE and hippocampal sclerosis using the same imaging method. Participants will undergo MRI scans while receiving one injection of ferumoxytol. Researchers will evaluate the quality of vascular images and measure vessel density in hippocampal subregions. Safety during infusion and scanning will be monitored closely. The study includes adults aged 18 to 64, both healthy and those with TLE. The main outcome is the enhanced imaging of cerebral vasculature using ferumoxytol during MRI. Participant involvement lasts for the duration of the scan and infusion procedure.
CONDITIONS
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
S
Sandy Arcand
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Alberta
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment visit
Participants receive an injection of Ferumoxytol to enhance MRI images while undergoing MRI scanning to assess cerebral vasculature.
1 visit (in-person) during which the injection and MRI scan occur
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Gerda B Toth, Csanad G Varallyay, Andrea Horvath...
https://pubmed.ncbi.nlm.nih.gov/28434822/Sarah Treit, Graham Little, Trevor Steve...
https://pubmed.ncbi.nlm.nih.gov/31819910/Shreyas S Vasanawala, Kim-Lien Nguyen, Michael D Hope...
https://pubmed.ncbi.nlm.nih.gov/26890830/Ingmar Blümcke, Maria Thom, Eleonora Aronica...
https://pubmed.ncbi.nlm.nih.gov/23692496/Ingmar Blümcke, Elisabeth Pauli, Hans Clusmann...
https://pubmed.ncbi.nlm.nih.gov/17221203/Sagar Buch, Yongsheng Chen, Pavan Jella...
https://pubmed.ncbi.nlm.nih.gov/35122968/Lisa C Adams, Praveen Jayapal, Shakthi K Ramasamy...
https://pubmed.ncbi.nlm.nih.gov/36197052/Kim-Lien Nguyen, Takegawa Yoshida, Nikhita Kathuria-Prakash...
https://pubmed.ncbi.nlm.nih.gov/31638489/J Paul Finn, Kim-Lien Nguyen, Peng Hu
https://pubmed.ncbi.nlm.nih.gov/28160356/Seyed Amir Ali Adel, Sarah Treit, Wasan Abd Wahab...
https://pubmed.ncbi.nlm.nih.gov/36461649/University of Alberta
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor